Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2017 09:00 ET | Source: uniQure Inc.

uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting

Non-human primate study of AMT-061 utilizing FIX-Padua shows 6.5-fold increase in FIX clotting activitycompared to AMT-060 Data supports nonclinical comparability plan agreed upon with FDA ...
November 01, 2017 09:10 ET | Source: uniQure Inc.

uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
November 01, 2017 07:00 ET | Source: uniQure Inc.

uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 31, 2017 16:02 ET | Source: uniQure Inc.

uniQure Announces Multiple Company Presentations at Upcoming November Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 27, 2017 16:03 ET | Source: uniQure Inc.

uniQure Announces Closing of its Public Offering

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 27, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 24, 2017 20:14 ET | Source: uniQure Inc.

uniQure Announces Pricing of its Public Offering

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 23, 2017 16:05 ET | Source: uniQure Inc.

uniQure Announces Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 23, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 19, 2017 07:05 ET | Source: uniQure Inc.

uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)

~ Issued Patent in the U.S. Covers Use of FIX-Padua in Gene Therapy ~ ~ Divisional patent applications filed to further strengthen Padua intellectual property position ~ LEXINGTON, Mass. and...
October 19, 2017 07:00 ET | Source: uniQure Inc.

uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018

~ AMT-060 with the FIX-Padua Modification (AMT-061) Demonstrates Substantial Increase in FIX Activity in Non-human Primates ~ ~ Plans to Initiate Pivotal Study with Enhanced AMT-061 in 2018 ~ ~...
October 18, 2017 07:00 ET | Source: uniQure Inc.

uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at the ESGCT 25th Anniversary Congress in Berlin

One-time Administration of AMT-130 Demonstrates Survival Benefit and Functional Improvement of Huntington’s Disease Symptoms in Preclinical Study IND-enabling Toxicology Study Initiated LEXINGTON,...